Nektar guts workforce, weeks after $3.6B Bristol Myers immuno-oncology collaboration ends
Nektar guts workforce, weeks after $3.6B Bristol Myers immuno-oncology collaboration [...]
Nektar guts workforce, weeks after $3.6B Bristol Myers immuno-oncology collaboration [...]
Trevena’s COVID-19 drug trial halted for inferiority, as NIH continues [...]
Another setback for Axsome as migraine med expected to get [...]
Vallon looks for escape route a month after sole clinical [...]
Astellas takes $170M hit as DMD gene therapy plan unravels [...]
The Clever-1? Faron hails melanoma data despite lack of responses [...]
Chutes & Ladders—Romanelli returns to Merck to lead international human [...]
Bayer nabs yet another oncology leader from GSK to bolster [...]
Novavax executives’ pay comes back down to Earth after 8-figure [...]
Using Knowledge Graphs to Drive Drug Discovery ncavazza Thu, 04/21/2022 [...]